Temozolomide Accord 100 mg hard capsules.
Sponsors
Tartu University Hospital, Institut De Recherches Internationales Servier IRIS, Helse Bergen HF, Medical University Of Vienna, Universitair Medisch Centrum Utrecht
Conditions
Diffuse Midline GliomaGlioblastoma MultiformeGrade IV recurrent glioma which includes both glioblastomaH3K27-alteredIDH1-mutant GliomaIDH2-mutant Gliomaclassified as IDH wt and grade IV IDH mutated astrocytoma.ependymoma and atypical teratoid rhabdoid tumor (ATRT)
Phase 1
BORTEZOMIB SENSITIZATION OF RECURRENT GRADE-4 GLIOMA WITH UNMETHYLATED MGMT PROMOTER TO TEMOZOLOMIDE. PHASE IB/II. (BORTEM 17)
RecruitingCTIS2024-515142-16-00
Start: 2024-10-03Target: 63Updated: 2024-10-02
A Phase 1b/2, multicenter study of vorasidenib in combination with temozolomide (TMZ) in participants with IDH1- or IDH2-mutant glioma
Active, not recruitingCTIS2024-513738-39-00
Start: 2025-03-18Target: 17Updated: 2025-12-18
FIDES: Focused Ultrasound-mediated Blood-Brain Barrier Opening In Pontine Diffuse Midline Glioma (DMG) to Enhance Systemic Therapy with Temozolomide – an exploratory pilot and feasibility trial
Not yet recruitingCTIS2025-520814-78-00
Target: 20Updated: 2026-03-23
Phase 2
A Phase 2, double-blind, placebo-controlled, randomized, proof-of-concept study evaluating LSTA1 when added to standard of care (temozolomide) versus temozolomide and matching LSTA1 placebo in subjects with newly diagnosed Glioblastoma Multiforme (GBM)
RecruitingCTIS2023-506813-23-00
Start: 2023-12-18Target: 40Updated: 2025-10-21
MEMMAT - Medulloblastoma European Multitarget Metronomic Anti-Angiogenic Trial - A Phase II study of metronomic and targeted anti-angiogenesis therapy for children with recurrent/progressive medulloblastoma, ependymoma, ATRT and rare CNS tumors
RecruitingCTIS2024-515626-92-00
Start: 2013-10-18Target: 100Updated: 2025-11-28